Q-omics provides the consensus-scored PLIN4 profile across patient tissues and cancer cell-line models. PLIN4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PLIN4 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, PLIN4 protein abundance shows 26,729 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRP, and HNSC as cancer lineages where PLIN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLIN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLIN4 survival associations across molecular data types. PLIN4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLIN4 RNA expression–survival associations across cancer types. High PLIN4 expression shows unfavorable associations in ACC, UCEC, OV and UCS, but favorable associations in KIRP and BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for PLIN4 RNA expression.
This table summarizes PLIN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLIN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLIN4 shows lower tumor expression in HNSC, BLCA, STAD, COAD, READ and BRCA. The HNSC box plot shows higher PLIN4 RNA expression in normal versus tumor tissue (log2 FC = −3.133, t-test p < 0.001).
This table shows molecular features associated with PLIN4 in patient tissues and cancer cell lines. In patient samples, PLIN4 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLIN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
